![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » US FDA AWARDS ISRAEL'S TEVA APPROVAL FOR ANTIFUNGAL PRODUCT
US FDA AWARDS ISRAEL'S TEVA APPROVAL FOR ANTIFUNGAL PRODUCT
Israel-based generics major Teva has announced that the abbreviated new drug application for its injectable antifungal Fluconazole has received final US FDA approval.
The treatment is a generic version of Pfizer's Diflucan, and is to be available as a 2 mg/mL dose, in 200- and 400-mg bags. Teva, which has not announced a launch date for the product, claims that the drug's branded and generic sales total some US$167mn per year.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct